Saniona AB (STO:SANION) announced on Thursday that the members of its nomination committee, for the 2018 Annual General Meeting, are Søren Skjærbæk, partner at Saxo lawyers, Vejle, Denmark, appointed by Jørgen Drejer; John Haurum, CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Thomas Feldthus and Claus Bræstrup, chairman of Saniona's board of directors.
Reportedly, the Annual General Meeting on 23 May 2017 had resolved that a nomination committee shall be appointed comprising of three members, which should be representatives of the two largest shareholders as of 30 September 2017, together with the chairman of the board of directors.
On 30 September 2017, the two largest shareholders, which desired to appoint a representative to the nomination committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative.
According to the company, this nomination committee shall prepare and submit proposals to the 2018 Annual General Meeting regarding election of the chairman at the AGM; election of the chairman and other members of the board; remuneration for the chairman and for each of the other members of the board and, if applicable, remuneration for committee work; election of the auditor and the auditor's remuneration and principles for appointing the nomination committee.
Saniona's Annual General Meeting will be held on 24 May 2018 in Malmö.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca